ARCT - Arcturus Therapeutics stock +6.1% despite Q3 miss

Arcturus Therapeutics ([[ARCT]] +6.0%) Q3 results:Collaboration revenue of $2.3M, compares with $3.3M last year, and misses consensus by $0.76M.Total operating expenses were $23.3M compares with $10.9M.Cash balance totaled $307.1M as of the end of Q3, compared to cash and cash equivalents of $71.5M at December 31, 2019.Net loss of ~$21M, or loss/share ($0.92), misses estimates by $0.44.Estimated revenue for Q4 of $3.41M and EPS of -$0.55.Executed definitive supply agreement with the Israeli Ministry of Health; up to $275M.Executed agreement with Singapore; $45M limited recourse loan facility and up to $175M in vaccine purchases.Dive deeper in earnings call transcriptPreviously: Arcturus Therapeutics EPS misses by $0.44, misses on revenue (Nov. 9)

For further details see:

Arcturus Therapeutics stock +6.1% despite Q3 miss